News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2020 PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years Michael O'Riordan March 30, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2020 More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA Michael O'Riordan March 28, 2020
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2019 Time and Money: PCI Public Reporting Requirements Take Their Toll Michael O'Riordan March 26, 2019
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2013 Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES Jason Kahn March 09, 2013
News Conference News ACC 2012 Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES Jason Kahn March 24, 2012